Effect of local zoledronate on implant osseointegration in a rat model

BMC Musculoskeletal Disorders

Research Article

Stephan Pauly¹  Norbert P Haas¹  Stefan H Greiner¹  Gerhard Schmidmaier²  David A Back³  Lisa Rommel⁴  Britt Wildemann⁴ 

[1] Center for Musculoskeletal Surgery, Charité-Universitaetsmedizin, Berlin, Germany;Department for Orthopedics, Traumatology and Paraplegiology, University of Heidelberg, Heidelberg, Germany;Department of Orthopedics and Traumatology, German Armed Forces Hospital Berlin, Berlin, Germany;Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin, Berlin, Germany;Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitaetsmedizin, Berlin, Germany;

关键词: Zoledronic Acid;    Pamidronate;    Ibandronate;    Release Kinetic;    Osseous Integration;   

DOI  :  10.1186/1471-2474-13-42

 received in 2011-09-12, accepted in 2012-03-22,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundAn implant coating with poly(D, L-lactide) (PDLLA) releasing incorporated Zoledronic acid (ZOL) has already proven to positively effect osteoblasts, to inhibit osteoclasts and to accelerate fracture healing. Aim of this study was to investigate the release kinetics of the chosen coating and the effect of different concentrations of ZOL locally released from this coating on the osseointegration of implants.MethodsFor release kinetics the release of C14-labled ZOL out of the coating was monitored over a period of six weeks in vitro. For testing the osseointegration, titanium Kirschner wires were implanted into the medullary canal of right femurs of 100 Sprague Dawley rats. The animals were divided into five groups receiving implants either uncoated or coated with PDLLA, PDLLA/ZOL low (1.2% w/w) or PDLLA/ZOL high (2% w/w). Additionally, a group with uncoated implants received ZOL intravenously (i.v.). After 56 days animals were sacrificed, femurs dissected and either strength of fixation or histological bone/implant contacts and newly formed bone around the implants were determined.ResultsRelease kinetics revealed an initial peak in the release of C14-ZOL with a slight further progression over the following weeks. There was no significant enhancement of osseointegration for both groups who received ZOL-coated implants or ZOL i.v. compared to the controls in biomechanical or histological analyses, except for a significant raise in strength of fixation of ZOL i.v. versus PDLLA.ConclusionsEven though the investigated local ZOL application did not enhance the osseointegration of the implant, the findings might support its application in fracture treatment, since fracture stabilization devices are often explanted after consolidation.

【 授权许可】

Unknown   
© Back et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.